Nurix Therapeutics

NURIX THERAPEUTICS INC

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Responding To Regulatory Scrutiny

Broad U.S. Equity ETFs

Education

Specialty ETFs

Tech

ETFs

ADPT

ARKG

ARKK

CDNA

COIN

CRSP

HOOD

IONS

NRIX

NTRA

PATH

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.

Cathie Wood&#39;s Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&amp;P 500

Wells Fargo

News

Price Target

Markets

Analyst Ratings

Trading Ideas

AFRM

ARCB

BNTC

BOOT

FAST

SNAP

Wells Fargo To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday

The Boeing Company (BA)

Earnings

Pre-Market Outlook

CLEU

IPHA

KARO

Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday

Nurix Therapeutics Inc

Management

Press Releases

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

Financing

Health Care

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Contracts

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

CareDx

Chimerix

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

89bio

Geron

GRAIL

Gyre Therapeutics

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

LENZ Therapeutics

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Myriad Genetics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Arcus Biosciences

Replimune Group

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Spyre Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Xencor

Zymeworks

HC Wainwright & Co.

Leerink Partners

Morgan Stanley

RBC Capital

JP Morgan

Comments

Nurix Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga